

11. (Amended) The method of Claim 8, wherein said chemotherapy is selected from the group consisting of chlorambucil (leukeran), prednisone, cyclophosphamide, a combination of cyclophosphamide, vincristine and prednisone (COP) [COP], a combination of cyclophosphamide, vincristine, prednisone and doxorubicin (CHOP) [CHOP] and Fludarabine.

12. (Amended) A method of treating a hematologic malignancy associated with high numbers of circulating tumor cells that is refractory to chemotherapy by administering a therapeutically effective amount of an anti-CD20 antibody or antigen-binding fragment thereof, said amount being effective to achieve a reduction in circulating tumor cells.

Kindly add the following new claims prior to further examination:

--13. A method of treating a hematological malignancy selected from the group consisting of B-prolymphocytic leukemia (B-PLL), chronic lymphocytic leukemia (CLL) and transformed non-Hodgkins lymphoma by administering a therapeutically effective amount of an anti-CD20 antibody or fragment thereof, said amount being effective to achieve a reduction in circulating tumor cells.

14. A method of avoiding or reducing the toxicity associated with administration of a therapeutic antibody to patients having a hematological malignancy associated with high numbers of circulating tumor cells, comprising administering said antibody according to a